In 2020, as Kexing Biopharm overcame the impact of COVID-19 and insisted on stable operation, it achieved a revenue of RMB 1.22 billion, net profit of RMB 139 million and net cash flow of RMB 106 million. Then, it kept enhancing the exploration of sales terminals and promoting fine market channels management. By 2020, Kexing Biopharm's products have been adopted by more than 16,000 sales terminals in China, including more than 6,000 hospitals, and have been registered in, exported and sold to more than 30 countries. Kexing Biopharm has achieved a sustained increase in R&D investment, up 30.20% year-on-year, accelerated the layout of innovative drug projects, and made steady progress in ongoing projects. Finally, it was listed on the Sci-Tech Innovation Board in the A-share market (stock code: 688136), which was deemed as a new historic leap.